Generalized anxiety disorder treatment
Silexan® 80 mg/day has demonstrated anxiolytic efficacy comparable to lorazepam 0.5 mg/day in a head-to-head RCT — without sedation, dependence risk, or cognitive impairment. Multiple large RCTs (including 539-patient and 318-patient trials) confirm significant reductions in Hamilton Anxiety Rating Scale scores, with effects appearing within 2 weeks.
Sleep quality improvement
Oral Silexan® significantly improves sleep quality, reduces sleep onset latency, and improves next-day functioning in adults with anxiety-related sleep disturbances. Unlike benzodiazepines and Z-drugs, lavender improves sleep architecture without suppressing deep sleep or REM stages, and produces no morning grogginess or rebound insomnia.
Mixed anxiety-depression improvement
Silexan® demonstrates efficacy for both anxiety and depressive components of mixed anxiety-depression disorder — producing significant improvements on both HAM-A and Montgomery-Åsberg Depression Rating Scales. The multi-neurotransmitter mechanism explains effects across both mood dimensions simultaneously.
Aromatherapy stress and relaxation effects
Inhaled lavender aromatherapy significantly reduces subjective anxiety, cortisol levels, and autonomic stress responses (heart rate, blood pressure) in acute stress studies. Effects are rapid — occurring within minutes of inhalation — through olfactory pathway-mediated limbic system modulation.
GABA-A receptor modulation
Linalool and linalyl acetate act as positive allosteric modulators at GABA-A receptors — enhancing inhibitory GABAergic neurotransmission without the sedative, amnesic, or dependency-producing effects of benzodiazepines. The binding site differs from benzodiazepines, explaining the absence of tolerance, dependence, and cognitive impairment.
Voltage-gated calcium channel inhibition
Lavender oil constituents inhibit voltage-gated calcium channels in neurons, reducing neuronal excitability and the hyperactivation of anxiety circuits in the amygdala and prefrontal cortex. This mechanism contributes to anxiolytic effects independently of GABA-A receptor modulation.
5-HT1A receptor partial agonism
Linalool acts as a partial agonist at 5-HT1A (serotonin type 1A) receptors — the same receptor targeted by buspirone (a non-benzodiazepine anxiolytic) and implicated in the mechanisms of SSRIs. 5-HT1A activation reduces anxiety and depressive symptoms through autoreceptor-mediated serotonin modulation in the raphe nucleus.
Randomized, double-blind, active-controlled trial of Silexan® (80 mg/day) vs. lorazepam (0.5 mg/day) vs. placebo in 77 generalized anxiety disorder patients for 6 weeks.
77 adults with generalized anxiety disorder. 6-week head-to-head design.
Silexan® produced equivalent anxiolytic efficacy to lorazepam (HAM-A total score reduction: -11.3 vs. -11.7 points). No sedation, cognitive impairment, or dependency with Silexan® vs. expected benzodiazepine profile. Established Silexan® as non-addictive, non-sedating anxiolytic.
Large randomized, double-blind, placebo-controlled trial of Silexan® (80 mg/day) vs. placebo in 539 adults with generalized anxiety disorder for 10 weeks.
539 adults with GAD. 10-week large-scale RCT.
Silexan® significantly reduced HAM-A total score, somatic and psychic anxiety subscores, and improved sleep quality and quality of life vs. placebo. Onset of action within 2 weeks. No dependency or withdrawal. Safety profile excellent.